 Ubiquitin-Protein Ligases
"Ubiquitin-Protein Ligases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A diverse class of enzymes that interact with UBIQUITIN-CONJUGATING ENZYMES and ubiquitination-specific protein substrates. Each member of this enzyme group has its own distinct specificity for a substrate and ubiquitin-conjugating enzyme. Ubiquitin-protein ligases exist as both monomeric proteins multiprotein complexes.
| Descriptor ID |
D044767
|
| MeSH Number(s) |
D08.811.464.938.750
|
| Concept/Terms |
Ubiquitin-Protein Ligases- Ubiquitin-Protein Ligases
- Ligases, Ubiquitin-Protein
- Ubiquitin Protein Ligases
- E3 Ubiquitin Ligase
- Ligase, E3 Ubiquitin
- Ubiquitin Ligase, E3
- Ubiquitin-Protein Ligase E3
- Ligase E3, Ubiquitin-Protein
- Ubiquitin Protein Ligase E3
- Ubiquitin Ligase E3
- Ligase E3, Ubiquitin
- Ubiquitin-Protein Ligase
- Ligase, Ubiquitin-Protein
- Ubiquitin Protein Ligase
- E3 Ligase
- Ligase, E3
|
Below are MeSH descriptors whose meaning is more general than "Ubiquitin-Protein Ligases".
Below are MeSH descriptors whose meaning is more specific than "Ubiquitin-Protein Ligases".
This graph shows the total number of publications written about "Ubiquitin-Protein Ligases" by people in this website by year, and whether "Ubiquitin-Protein Ligases" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 | | 2000 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 0 | 2 | 2 | | 2004 | 0 | 2 | 2 | | 2005 | 0 | 3 | 3 | | 2006 | 1 | 4 | 5 | | 2007 | 2 | 4 | 6 | | 2008 | 5 | 0 | 5 | | 2009 | 1 | 5 | 6 | | 2010 | 1 | 2 | 3 | | 2011 | 1 | 3 | 4 | | 2012 | 5 | 2 | 7 | | 2013 | 3 | 7 | 10 | | 2014 | 6 | 4 | 10 | | 2015 | 7 | 2 | 9 | | 2016 | 5 | 1 | 6 | | 2017 | 6 | 4 | 10 | | 2018 | 0 | 1 | 1 | | 2019 | 2 | 3 | 5 | | 2020 | 8 | 1 | 9 | | 2021 | 3 | 2 | 5 | | 2022 | 1 | 2 | 3 | | 2023 | 2 | 2 | 4 | | 2024 | 3 | 3 | 6 | | 2025 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Ubiquitin-Protein Ligases" by people in Profiles.
-
Sampath R, Vaeth K, Mikalayeva V, Skeberdis VA, Prekeris R, Han KJ. Rab40 GTPases regulate AMBRA1-mediated transcription and cell migration. J Cell Sci. 2025 Apr 01; 138(7).
-
Briney CA, Henriksen JC, Lin C, Jones LA, Benner L, Rains AB, Gutierrez R, Gafken PR, Rissland OS. Muskelin is a substrate adaptor of the highly regulated Drosophila embryonic CTLH E3 ligase. EMBO Rep. 2025 Mar; 26(6):1647-1669.
-
Oguh AU, Haemmerle MW, Sen S, Rozo AV, Shrestha S, Cartailler JP, Fazelinia H, Ding H, Preza S, Yang J, Yang X, Sussel L, Alvarez-Dominguez JR, Doliba N, Spruce LA, Arrojo E Drigo R, Stoffers DA. E3 ligase substrate adaptor SPOP fine-tunes the UPR of pancreatic ? cells. Genes Dev. 2025 Feb 03; 39(3-4):261-279.
-
Blears D, Lou J, Fong N, Mitter R, Sheridan RM, He D, Dirac-Svejstrup AB, Bentley D, Svejstrup JQ. Redundant pathways for removal of defective RNA polymerase II complexes at a promoter-proximal pause checkpoint. Mol Cell. 2024 Dec 19; 84(24):4790-4807.e11.
-
Bricelj A, Dora Ng YL, Gobec M, Kuchta R, Hu W, Javornik ?, Ro?ic M, G?tschow M, Zheng G, Kr?nke J, Steinebach C, Sosic I. Design, Synthesis, and Evaluation of BCL-2 Targeting PROTACs. Chemistry. 2024 Aug 12; 30(45):e202400430.
-
Broderick A, Pan E, Li J, Chu A, Hwang C, Barata PC, Cackowski FC, Labriola M, Ghose A, Bilen MA, Kilari D, Thapa B, Piero M, Graham L, Tripathi A, Garje R, Koshkin VS, Hernandez E, Dorff TB, Schweizer MT, Alva AS, McKay RR, Armstrong AJ. Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancer. Prostate Cancer Prostatic Dis. 2025 Jun; 28(2):419-426.
-
Plimack ER, Tangen C, Plets M, Kokate R, Xiu J, Nabhan C, Ross EA, Grundy E, Choi W, Dinney CPN, Lee IC, Fong M, Scott Lucia M, Daneshmand S, Theodorescu D, Goldkorn A, Lerner SP, Flaig TW, McConkey DJ. Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial. Eur Urol. 2024 Oct; 86(4):297-300.
-
Karayol R, Borroto MC, Haghshenas S, Namasivayam A, Reilly J, Levy MA, Relator R, Kerkhof J, McConkey H, Shvedunova M, Petersen AK, Magnussen K, Zweier C, Vasileiou G, Reis A, Savatt JM, Mulligan MR, Bicknell LS, Poke G, Abu-El-Haija A, Duis J, Hannig V, Srivastava S, Barkoudah E, Hauser NS, van den Born M, Hamiel U, Henig N, Baris Feldman H, McKee S, Krapels IPC, Lei Y, Todorova A, Yordanova R, Atemin S, Rogac M, McConnell V, Chassevent A, Bara?ano KW, Shashi V, Sullivan JA, Peron A, Iascone M, Canevini MP, Friedman J, Reyes IA, Kierstein J, Shen JJ, Ahmed FN, Mao X, Almoguera B, Blanco-Kelly F, Platzer K, Treu AB, Quilichini J, Bourgois A, Chatron N, Januel L, Rougeot C, Carere DA, Monaghan KG, Rousseau J, Myers KA, Sadikovic B, Akhtar A, Campeau PM. MSL2 variants lead to a neurodevelopmental syndrome with lack of coordination, epilepsy, specific dysmorphisms, and a distinct episignature. Am J Hum Genet. 2024 07 11; 111(7):1330-1351.
-
Ramirez AT, Liu Z, Xu Q, Nowosadtko S, Liu X. Cloflucarban Illuminates Specificity and Context-Dependent Activation of the PINK1-Parkin Pathway by Mitochondrial Complex Inhibition. Biomolecules. 2024 Feb 20; 14(3).
-
Tencer AH, Yu Y, Causse SZ, Campbell GR, Klein BJ, Xuan H, Cartier J, Miles MA, Gaurav N, Zadoroznyj A, Holt TA, Wen H, Hawkins CJ, Spector SA, Dubrez L, Shi X, Kutateladze TG. Molecular basis for nuclear accumulation and targeting of the inhibitor of apoptosis BIRC2. Nat Struct Mol Biol. 2023 09; 30(9):1265-1274.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|